Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.14.16.2 (
tyrosine hydroxylase
)
14,760
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dihydralazine
treatment which lowered blood pressure in young rats from the Lyon Hypertensive Strain (LHS), did not change phenylethanolamine-N-methyltransferase (PNMT) activity, but decreased
tyrosine hydroxylase
and dopamine-beta-hydroxylase activities in the C2 medullary region. These data suggest that the increase in PNMT activity, previously described for this strain, is not a consequence of the developing hypertension and that hypotensive treatment could inactivate some catecholaminergic neurons of the medulla oblongata.
...
PMID:Dihydralazine and catecholamine-synthesizing enzymes in spontaneous hypertension. 49 52
The effect of dihydralazine on monoamine metabolism in the rat was investigated.
Dihydralazine
, 5 mg/kg i.v., reduced noradrenaline (NA) in the heart. After pretreatment with phenoxybenzamine an NA depletion was evident also in the brain.
Dihydralazine
did not affect the utilization of NA or dopamine in the brain as judged by the disappearance rates of these amines following synthesis inhibition by alpha-methyl-p-tyrosine. However, dihydralazine reduced the synthesis of monoamines as evidenced by a decreased accumulation of the monamine precursor dihydroxyphenylalanine (and 5-hydroxytryptamine) subsequent to treatment with NSD 1015. It is concluded that dihydralazine inhibits central
tyrosine hydroxylase
(and tryptophan hydroxylase) in the rat.
...
PMID:Dihydralazine inhibits tyrosine hydroxylase in vivo in the rat. 612 15
Dihydralazine
, which is used in the treatment of hypertension, causes a long-lasting hypotensive action by a direct vasodilator effect on arteriolar smooth muscle. The present study was carried out to investigate the effect of a daily single injection of dihydralazine (20 mg/kg, s.c.) for 14 days on the
tyrosine hydroxylase
(TH) protein quantity in some catecholaminergic rat brainstem areas such as the dorsomedial medulla (DMM), the ventrolateral medulla (VLM) and the locus coeruleus (LC). This study demonstrates that the dihydralazine produced (1) an 85% increase in TH protein quantity exclusively in the rostral part of DMM, (2) a 58% increase of TH protein content exclusively in the rostral part of the LC, and (3) a 37% increase of the TH protein quantity in VLM catecholaminergic area. To determine whether the increase in TH protein quantity could be related to a change in norepinephrine (NE) content, the rate constant of disappearance (k) of NE was measured in the catecholaminergic regions of the same rats treated with dihydralazine. Our results show that dihydralazine causes an increase of the TH protein, in addition to an elevation of NE content, within the subpopulations of catecholaminergic structures. These data suggest a selective response of the TH regulation to dihydralazine within the rostral DMM area which receives barosensory inputs.
...
PMID:Regional specificity of long-term regulation of tyrosine hydroxylase in some catecholaminergic rat brainstem areas. II. Effect of a chronic dihydralazine treatment. 810 Jan 76